HIV-1 reverse transcriptase variants: Molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method

Drug Design and Discovery

Volumn 18, Issue 4, 2003, Pages 151-163

  Kroeger Smith, Marilyn B ^a,b   Ruby, Sandra ^b   Horouzhenko, Stanislav ^b   Buckingham, Bryan ^b   Richardson, Julia ^b   Puleri, Ina ^b   Potts, Emily ^b   Jorgensen, William L ^c   Arnold, Edward ^d   Zhang, Wanyi ^d   Hughes, Stephen H ^a   Michejda, Christopher J ^a   Smith Jr , Richard H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCDANIEL COLLEGE   (United States)

^c YALE UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

HIV 1 reverse transcriptase variants; Monte Carlo simulations

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CALCULATION; CORRELATION ANALYSIS; CRYSTALLOGRAPHY; DATA ANALYSIS; DRUG SYNTHESIS; ENERGY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; LINEAR SYSTEM; MOLECULAR MODEL; MONTE CARLO METHOD;

ALGORITHMS; COMPUTER SIMULATION; DATABASES, PROTEIN; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; HYDROGEN BONDING; LINEAR MODELS; MODELS, MOLECULAR; MONTE CARLO METHOD; MUTATION; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4344598167     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: 10.1080/10559610390484203     Document Type: Article

References (32)

1. Larder, B. A., and Kemp, S. D. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). Science, 246, 1155-1158.
2. St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., and Larder, B. A. (1991). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science, 253, 1557-1559.
3. Richman, D. D. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol., 68, 1660-1666.
4. Zhang, D., Caliendo, A. M., Eron, J. J, DeVore, K. M., Kaplan, J. C., Hirsch, M. S., and D'auuila, R. T. (1994). Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 38, 282-287.
5. Boyer, P. L., Ding, J., Arnold, E., and Hughes, S. H. (1994). Subunit specificity of mutations that confer resistance to nonucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 38, 1909-1914.
6. Boyer, P. L., Tantillo, C., Jacobo-Molina, A., Nanni, R. G., Ding, J., Arnold, E., and Hughes, S. H. (1994). Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci., USA, 91, 4882-4886.
7. Moermans, M., De Raeymaeker, M., Boeckx, I., Van den Broeck, R., Stoffels, P., De Brabander, M., De Cree, J., Hertogs, K., Pauwels, R., Staszewski, S., and Andries, K. (1995). Virological analysis of HIV-1 isolates in patients treated with the non-nucleoside reverse transcriptase inhibitor R091767 (8-Cl TIBO). Abstracts of the Fourth International Workshop on HVI-1 Drug Resistance, Sardinia, Italy.
8. Metropolis, N., and Ulam, S. (1949). The Monte Carlo method. J. Am. Stat. Assoc., 44, 335-341.
9. Jorgensen, W. L. (1998). MCPRO, Version 1.6. New Haven, CT: Yale University.
10. Aqvist, J., Medina, C., and Samuelsson, J.-E. (1994). A new method for predicting binding affinity in computer-aided drug design. Prot. Eng., 7, 385-391.
11. Carlson, H. A., and Jorgensen, W. L. (1995). An extended linear response method for determining free energies of hydration. J. Phys. Chem., 99, 10667-10673.
12. McDonald, N. A., Carlson, H. A., and Jorgensen, W. L. (1997). Free energies of solvation in choroform and water from a linear response approach. J. Phys. Org. Chem., 10, 563-576.
13. Hertzog-Jones, D. K., and Jorgensen W. L. (1997). Binding affinities for sulfoamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method. J. Med. Chem., 40, 1539-1549.
14. Lamb, M. L., and Jorgensen. W. L. (1999). Investigations of neurotropic inhibitors of FK506 binding protein via Monte Carlo simulations. J. Med. Chem., 41, 3928-3939.
15. Lamb, M. L., Tirado-Rives, J., and Jorgensen, W. L. (1999). Estimation of the binding affinities of FKBP12 inhibitors using a linear response method. Bioorg. Med. Chem., 7, 851-860.
16. Pierce, A. C., and Jorgensen, W. L. (1997). Computational binding affinities for trypsin benzamidine complexes via free energy perturbations. J. Phys. Chem. B, 36, 1466-1469.
17. Smith, R. H., Jr., Jorgensen, W. L., Tirado-Rives, J., Lamb, M. L., Janssen, P. A. J., Michejda, C. J., and Kroeger Smith, M. B. (1998). Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J. Med. Chem., 41, 5272-5286.
18. Rizzo, R. C., Tirado-Rives, J., and Jorgensen, W. L. (2001). Estimation of binding affinities for HEPT and nevirapine analogs with HIV-1 reverse transcriptase via Monte Carlo simulations. J. Med. Chem., 44, 145-154.
19. Rizzo, R. C., Blagovic, M. U., Wang, D.-P., Watkins, E. K., Smith, M. B. K. K., Smith, R. H., Jr., Tirado-Rives, J., and Jorgensen, W. L. (2002). Prediction of activity for non-nucleoside inhibitors with HIV reverse transcriptase based on Monte Carlo simulations. J. Med. Chem., 45, 2970-2987.
20. Kroeger Smith, M., Hose, B. M., Hawkins, A., Lipchock, J., Farnsworth, D. W., Rizzo, R. C., Tirado-Rives, Arnold, E., Zhang, W.. Hughes, S. H., Jorgensen, W. L., Farnsworth, D. W., Michejda, C. J., and Smith, R. H., Jr. (2003). Molecular modeling calculations of, HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogs, J. Med. Chem., 46, 1940-1947.
21. Roth, T., Morningstar, M. L., Boyer, P. L., Hughes, S. H., Buckheit, R. W., Jr., and Michejda, C. J. (1997). Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. J. Med. Chem., 40, 4199-4207.
22. Morningstar, M. L., Roth, T., Smith, M. Kroeger, Zajac, M., Watson, K., Buckheit, R. W., Jr., and Michejda, C. J. (2004). Synthesis and biological activity of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J. Med. Chem., to appear.
23. Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P. A. J., Hughes, S. H., and Arnold, E. (1995). Structure of HIV-1 RT/TIBO R86183 complex reveals remarkable similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct. Biol., 2, 407-415.
24. Kroeger Smith, M. B., Lamb, M. L., Tirado-Rives, J., Jorgensen, W. L., Michejda, C. J., Ruby, S. K., and Smith, R. H., Jr. (2000). Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor 8-Cl TIBO: Contribution of the L100I and Y181C variants to protein stability and biological activity. Prot. Eng., 13, 413-421.
25. Das, K., Ding, J., Hsiou, Y., Clark, A. D., Jr., Moereels, H., Koymans, L., Andries, K., Pauwels, R., Janssen, P. A. J., Boyer, P. D., Clark, P., Smith, R. H., Jr., Kroeger Smith, M. B., Michejda, C. J., Hughes, S. H., and Arnold, E. (1996). Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIVRT and 8-Cl TIBO complexed with the tyr181 cys HIV-1 RT drug resistant mutant. J. Mol. Biol., 264, 1085-1100.
26. Kroeger Smith, et al., unpublished data.
27. Jorgensen, W. L. (2003). Biochemical and Organic Model Builder (BOMB), Version 2.3, New Haven, CT: Yale University Press.
28. Jorgensen, W. L., unpublished data.
29. E. Arnold, Rutgers University, New Branswick, NJ, unpublished data.
30. R. W. Buckheit, Jr., personal communication.
31. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
32. JMP-Jn, Version 4 (2001). SAS Institute Inc., Cary, NC.